# US 2022/0017491 A1 · Compound inhibiting yap-tead binding, and pharmaceutical composition for preventing or treating cancer, comprising compound as active ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017491 A1
- Document ID: US20220017491A1
- Status: Published application
- Kind: A1
- Application number: 17/292,699
- Filed: 2019-11-08
- Published: 2022-01-20
- Earliest claimed: 2018-11-09
- Assignees: Korea Research Institute of Chemical Technology; Industry-Academic Cooperation Foundation, Yonsei University
- Applicants: Korea Research Institute of Chemical Technology; Industry-Academic Cooperation Foundation, Yonsei University
- Inventors: Hwan Jung LIM; Seong Jun PARK; Chang Hoon LEE; Kyoung Tai NO; Jiwon CHOI; Hei-Cheul JEUNG; You-keun SHIN; Jong Wan KIM; Xuemei JIN
- Web page: https://patentgrep.com/patent/US20220017491A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound which inhibits the binding of Yes associated protein (YAP) and transcriptional enhancer associate domain (TEAD), a prodrug of same, a hydrate of same, a solvate of same or a pharmaceutically acceptable salt of same, and a composition comprising same as an active ingredient, the compound according to the present invention being able to be applied as an inhibitor which can directly inhibit YAP-TEAD binding in the Hippo pathway which plays a crucial role in the occurrence of cancer.

## Claims

### Claim 1

A compound represented by the following Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof:
wherein
Ra is hydrogen or -L-R3;
R1 is hydrogen or —(CH2)n—R;
R is C1-C10alkoxy, C6-C20aryloxy, hydroxy, C1-C10alkylcarbonyloxy, C6-C20arylcarbonyloxy, cyano, halogen, nitro, C1-C10alkylsulfanyl, C6-C20arylsulfanyl, sulfanyl, —NRa1Ra2, C1-C10alkoxyC1-C10alkyl, C6-C20aryloxyC1-C10alkyl, C1-C10alkoxyC1-ClOalkoxy, C1-C10alkoxyC1-C10alkoxyC1-C10alkyl, C1-C10alkylsulfonyl, C6-C20arylsulfonyl, C1-C10alkylC6-C20arylsulfonyl, C6-C20arylC1-C10alkylsulfonyl, sulfo, C6-C20aryl, C3-C20cycloalkyl, carbamoyl, C1-C10alkylaminocarbonyl, C6-C20arylaminocarbonyl, sulfamoyl, C1-C10alkylaminosulfonyl, C6-C20arylaminosulfonyl, C1-C10alkylcarbonyl, C6-C20arylcarbonyl, C1-C10alkoxycarbonyl, C6-C20aryloxycarbonyl, carboxyl, formyl, C2-C20heteroaryl, or C3-C20heterocycloalkyl, and the aryl, heteroaryl, and heterocycloalkyl of R may be further substituted by one or more substituents selected from the group consisting of C1-ClOalkyl, halogen, nitro, cyano, hydroxy, C1-C10alkoxy, C6-C20aryloxy, C1-C10alkylsulfanyl, haloC1-C10alkylsulfanyl, C6-C20arylsulfanyl, diC1-C10alkylamino, C1-C10alkylsulfonyl, C6-C20arylsulfonyl, C1-C10alkylC6-C20arylsulfonyl, C6-C20arylC1-C10alkylsulfonyl, C3-C20cycloalkyl, carboxyl, sulfo, formyl, carbamoyl, sulfamoyl, amino, C1-C10alkylcarbonyl, C6-C20arylcarbonyl, C1-C10alkoxycarbonyl, C6-C20aryloxycarbonyl, C1-C10alkylcarbonyloxy, C6-C20arylcarbonyloxy, C2-C20heteroaryl, and C3-C20heterocycloalkyl;
Ra1 and Ra2 are independently of each other hydrogen, C1-C10alkyl, C1-C10alkylsulfonyl, C6-C20arylsulfonyl, C1-C10alkylC6-C20arylsulfonyl, C6-C20arylC1-C10alkylsulfonyl, sulfo, C6-C20aryl, C3-C20cycloalkyl, or sulfamoyl;
n is an integer of 1 to 10;
R2 is hydrogen, C1-C10alkyl, C1-C10alkoxyC1-C10alkyl, C3-C20cycloalkyl, C3-C20cycloalkyloxyC1-C10alkyl, C6-C20aryl, or C6-C20aryloxyC1-C10alkyl;
X is CH or N;
Z is —CH2— or —CO—;
L is —SO2—, —SO2-L′-, —NHCO—, —CONH—, C1-C10 alkylene, or —CO—;
L′ is —NH— or
La is C1-C10alkylene;
n1 is an integer of 1 to 3;
m1 is an integer of 0 or 1;
with a proviso that (i) when X is CH, L is necessarily —SO2—NH—, and
(ii) when L is C1-C10 alkylene, a case in which R3 is C1-C10alkyl, C1-C10alkoxy, or C6-C20aryloxy is excluded;
R3 is C1-C10alkyl, C1-C10alkoxy, C6-C20aryloxy, C3-C20heterocycloalkyl, C6-C20aryl, or C2-C20heteroaryl, and the heterocycloalkyl, aryl, and heteroaryl of R3 may be further substituted by one or more substituents selected from the group consisting of C1-C10alkyl, halogen, haloC1-C10alkyl, nitro, cyano, C1-C10alkylcarbonylamino, C6-C20arylcarbonylamino, amino, C1-C10alkoxy, haloC1-C10alkoxy, C1-C10alkoxyC1-C10alkoxy, C6-C20aryloxy, hydroxy, C1-C10alkylcarbonyl, haloC1-C10alkylcarbonyl, C6-C20arylcarbonyl, C1-C10alkoxycarbonyl, C6-C20aryloxycarbonyl, carboxyl, formyl, sulfanyl, C1-C10alkylsulfanyl, C6-C20arylsulfanyl, diC1-C10alkylaminoC1-C10alkoxy, dihydroxyaminosulfanyl, C1-C10alkylsulfonyl, C6-C20arylsulfonyl, C1-C10alkylC6-C20arylsulfonyl, C6-C20arylC1-C10alkylsulfonyl, sulfo, carbamoyl, C1-C10alkylaminocarbonyl, C6-C20arylaminocarbonyl, sulfamoyl, C1-C10alkylaminosulfonyl, C6-C20arylaminosulfonyl, C6-C20aryl, C2-C20heteroaryl, C1-C10alkylcarbonyloxy, C6-C20arylcarbonyloxy, and C3-C20heterocycloalkyl;
R4 is halogen, haloC1-C10alkyl, cyano, C1-C10alkyl, C6-C20aryl, C2-C20heteroaryl, C1-C10alkoxy, C6-C20aryloxy, C2-C20heteroaryloxy, haloC1-C10alkoxy, hydroxy, amino, or aminoC1-C10alkyl;
d is an integer of 0 to 5, and when d is an integer of 2 or more, R4 may be the same as or different from each other;
a and b are independently of each other an integer of 0, 1, or 2, and a+b is an integer of 1, 2 or 3; and
the heteroaryl and the heterocycloalkyl contains one or more heteroatoms selected from nitrogen, oxygen, and sulfur.

### Claim 2 (depends on 1)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein the compound is represented by the following Chemical Formula 2:
wherein R1, R2, X, Z, L, R3, R4, a, b, and d are as defined in Chemical Formula 1 of claim 1.

### Claim 3 (depends on 2)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 2, wherein the compound is represented by the following Chemical Formula 3, 4, 5, 6, or 7:
wherein R1, R2, Z, L, R3, R4, and d are as defined in Chemical Formula 2 of claim 2.

### Claim 4 (depends on 1, 2)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein the compound is represented by the following Chemical Formula 8, 9, or 10:
wherein R1, R2, R3, R4, and d are as defined in Chemical Formula 2 of claim 2.

### Claim 5 (depends on 2, 3)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 3, wherein the compound is represented by any one selected from the following Chemical Formulae 11 to 25:
wherein R1, R2, R3, R4, and d are as defined in Chemical Formula 2 of claim 2;
R3a is C3-C20heterocycloalkyl, C6-C20aryl, or C2-C20heteroaryl, and the heterocycloalkyl, aryl, and heteroaryl of R3a may be further substituted by one or more substituents selected from the group consisting of C1-C10alkyl, halogen, haloC1-C10alkyl, nitro, cyano, C1-ClOalkylcarbonylamino, C6-C20arylcarbonylamino, amino, C1-C10alkoxy, haloC1-C10alkoxy, C1-C10alkoxyC1-C10alkoxy, C6-C20aryloxy, hydroxy, C1-C10alkylcarbonyl, haloC1-C10alkylcarbonyl, C6-C20arylcarbonyl, carboxyl, formyl, sulfanyl, C1-C10alkylsulfanyl, C6-C20arylsulfanyl, diC1-C10alkylaminoC1-C10alkoxy, dihydroxyaminosulfanyl, C1-C10alkylsulfonyl, C6-C20arylsulfonyl, sulfo, carbamoyl, C1-C10alkylaminocarbonyl, C6-C20arylaminocarbonyl, sulfamoyl, C1-C10alkylaminosulfonyl, C6-C20arylaminosulfonyl, C6-C20aryl, C2-C20heteroaryl, and C3-C20heterocycloalkyl; and
La is C1-C5alkylene.

### Claim 6 (depends on 4)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 4, wherein
R1 is hydrogen or —(CH2)n—R;
R is C1-C6alkoxy, C6-C12aryloxy, hydroxy, cyano, halogen, nitro, C1-C6alkylsulfanyl, C6-C12arylsulfanyl, sulfanyl, —NRa1Ra2, C1-C6alkoxyC1-C6alkyl, C6-C12aryloxyC1-C6alkyl, C1-C6alkoxyC1-C6alkoxy, C1-C6alkoxyC1-C6alkoxyC1-C6alkyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C1-C6alkylC6-C12arylsulfonyl, C6-C12arylC1-C6alkylsulfonyl, sulfo, C6-C12aryl, C1-C6alkoxycarbonyl, C6-C12aryloxycarbonyl, carboxyl, formyl, C2-C12heteroaryl, or C3-C12heterocycloalkyl, and the aryl, heteroaryl, and heterocycloalkyl of R may be further substituted by one or more substituents selected from the group consisting of C1-C6alkyl, halogen, nitro, cyano, hydroxy, C1-C6alkoxy, C6-C12aryloxy, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C1-C6alkylC6-C12arylsulfonyl, C6-C12arylC1-C6alkylsulfonyl, carboxyl, sulfo, formyl, carbamoyl, sulfamoyl, and amino;
Ra1 and Ra2 are independently of each other hydrogen, C1-C6alkyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C1-C6alkylC6-C12arylsulfonyl, C6-C12arylC1-C6alkylsulfonyl, sulfo, or sulfamoyl;
n is an integer of 1 to 5;
R2 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl, or C6-C12aryloxyC1-C6alkyl;
R3 is C1-C6alkyl, C1-C6alkoxy, C6-C12aryloxy, C3-C12heterocycloalkyl, C6-C12aryl, or C2-C12heteroaryl;
R3a is C3-C12heterocycloalkyl, C6-C12aryl, or C2-C12heteroaryl;
the heterocycloalkyl, aryl, and heteroaryl of R3 and R3a may be further substituted by one or more substituents selected from the group consisting of C1-C6alkyl, halogen, haloC1-C6alkyl, nitro, cyano, C1-C6alkylcarbonylamino, C6-C12arylcarbonylamino, amino, C1-C6alkoxy, haloC1-C6alkoxy, C1-C6alkoxyC1-C6alkoxy, C6-C12aryloxy, hydroxy, C1-C6alkylcarbonyl, haloC1-C6alkylcarbonyl, C6-C12arylcarbonyl, carboxyl, formyl, sulfanyl, C1-C6alkylsulfanyl, C6-C12arylsulfanyl, diC1-C6alkylaminoC1-C6alkoxy, dihydroxyaminosulfanyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, sulfo, carbamoyl, C1-C6alkylaminocarbonyl, C6-C12arylaminocarbonyl, sulfamoyl, C1-C6alkylaminosulfonyl, C6-C12arylaminosulfonyl, C6-C12aryl, C2-C12heteroaryl, and C3-C12heterocycloalkyl;
La is C1-C5alkylene;
R4 is halogen, haloC1-C6alkyl, cyano, C1-C6alkyl, C6-C12aryl, C2-C12heteroaryl, C1-C6alkoxy, C6-C12aryloxy, C2-C12heteroaryloxy, haloC1-C6alkoxy, hydroxy, amino, or aminoC1-C6alkyl; and
d is an integer of 0 to 5, and when d is an integer of 2 or more, R4 may be the same as or different from each other.

### Claim 7 (depends on 6)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 6, wherein
R1 is hydrogen or —(CH2)n—R;
R is C1-C6alkoxy, hydroxy, cyano, halogen, C1-C6alkylsulfanyl, —NRa1Ra2, C1-C6alkoxyC1-C6alkyl, C1-C6alkoxyC1-C6alkoxy, C1-C6alkoxyC1-C6alkoxyC1-C6alkyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C6-C12aryl, C1-C6alkoxycarbonyl, C6-C12aryloxycarbonyl, C2-C12heteroaryl, or C3-C12heterocycloalkyl, and the aryl, heteroaryl, and heterocycloalkyl of R may be further substituted by one or more substituents selected from the group consisting of C1-C6alkyl, halogen, nitro, cyano, hydroxy, C1-C6alkoxy, C6-C12aryloxy, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C1-C6alkylC6-C12arylsulfonyl, C6-C12arylC1-C6alkylsulfonyl, carboxyl, sulfo, and formyl;
Ra1 and Ra2 is independently of each other C1-C6alkyl, C1-C6alkylsulfonyl, or C6-C12arylsulfonyl;
n is an integer of 1 to 3;
R2 is hydrogen or C1-C6alkoxyC1-C6alkyl;
R3 is C1-C6alkyl, C1-C6alkoxy, C3-C12heterocycloalkyl, C6-C12aryl, or C2-C12heteroaryl;
R3a is C3-C12heterocycloalkyl, C6-C12aryl, or C2-C12heteroaryl;
the heterocycloalkyl, aryl, and heteroaryl of R3 and R3a may be further substituted by one or more substituents selected from the group consisting of C1-C6alkyl, halogen, haloC1-C6alkyl, nitro, cyano, C1-C6alkylcarbonylamino, C6-C12arylcarbonylamino, amino, C1-C6alkoxy, haloC1-C6alkoxy, C1-C6alkoxyC1-C6alkoxy, hydroxy, C1-C6alkylcarbonyl, haloC1-C6alkylcarbonyl, C6-C12arylcarbonyl, carboxyl, formyl, sulfanyl, C1-C6alkylsulfanyl, C6-C12arylsulfanyl, diC1-C6alkylaminoC1-C6alkoxy, dihydroxyaminosulfanyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, sulfo, carbamoyl, sulfamoyl, C6-C12aryl, C2-C12heteroaryl, and C3-C12heterocycloalkyl;
R4 is halogen, haloC1-C6alkyl, cyano, C1-C6alkyl, C6-C12aryl, C2-C12heteroaryl, C1-C6alkoxy, C6-C12aryloxy, C2-C12heteroaryloxy, haloC1-C6alkoxy, hydroxy, amino, or aminoC1-C6alkyl; and
d is an integer of 0 to 5, and when d is an integer of 2 or more, R4 may be the same as or different from each other.

### Claim 8 (depends on 7)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 7, wherein R1 is hydrogen.

### Claim 9 (depends on 7)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 7, wherein
R1 is —(CH2)n—OR1, —(CH2)n—OH, —(CH2)n—CN, —(CH2)n—X1, —(CH2)n—SR12, —(CH2)n—NR13R14, —(CH2)n—NR13—SO2R15, —(CH2)n-L1-OR11, —(CH2)n—SO2R16, or —(CH2)n—C(═O)OR17, or is selected from the following structures:
wherein R11 is C1-C4alkyl or C1-C4alkoxyC1-C4alkyl;
X1 is halogen;
R12 to R14 are independently of each other C1-C4alkyl;
R15, R16, R17, and R20 are independently of one another C1-C4alkyl or C6-C12aryl;
L1 is C1-C4 alkylene;
R18 and R19 are independently of each other C1-C4alkyl, halogen, nitro, cyano, hydroxy, C1-C4alkoxy, C6-C12aryloxy, carboxyl, sulfo, or formyl;
R′ is hydrogen or C1-C4alkyl;
Q is CH2, NH, O, or S;
n is an integer of 1 to 3;
p is an integer of 0 to 5, and when p is an integer of 2 or more, R18 may be the same as or different from each other; and
q is an integer of 0 to 4, and when q is an integer of 2 or more, R19 may be the same or different from each other.

### Claim 10 (depends on 7)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 7, wherein
R2 is hydrogen or C1-C4alkoxyC1-C4alkyl;
R3 is selected from C1-C4alkyl, C1-C4alkoxy, or the following structures:
R21 to R26 are independently of each one another C1-C4alkyl, halogen, haloC1-C4alkyl, nitro, cyano, C1-C4alkylcarbonylamino, C6-C12arylcarbonylamino, amino, C1-C4alkoxy, haloC1-C4alkoxy, C1-C4alkoxyC1-C4alkoxy, hydroxy, C1-C4alkylcarbonyl, haloC1-C4alkylcarbonyl, C6-C12arylcarbonyl, carboxyl, formyl, sulfanyl, C1-C4alkylsulfanyl, C6-C12arylsulfanyl, diC1-C4alkylaminoC1-C4alkoxy, dihydroxyaminosulfanyl, C1-C4alkylsulfonyl, C6-C12arylsulfonyl, sulfo, carbamoyl, sulfamoyl, C6-C12aryl, C2-C12heteroaryl, or C3-C12heterocycloalkyl;
Y1 and Y2 are independently of each other NR″, O, or S;
Z is —(CR27R28)x—;
R27 and R28 are independently of each other hydrogen, C1-C4alkyl, or halogen;
x is an integer of 1 to 3;
T is CH2 or O;
R″ is hydrogen or C1-C4alkyl; and
r is an integer of 0 to 3, and when r is an integer of 2 or more, R21 may be the same as or different from each other; s is an integer of 0 to 2, and when s is an integer of 2 or more, R22 may be the same as or different from each other; t is an integer of 0 to 4, and when t is an integer of 2 or more, R23 may be the same as or different from each other; u is an integer of 0 to 5, and when u is an integer of 2 or more, R24 may be the same as or different from each other; v is an integer of 0 to 6, and when v is an integer of 2 or more, R25 may be the same as or different from each other; and w is an integer of 0 to 7, and when w is an integer of 2 or more, R26 may be the same as or different from each other;
R4 is halogen, haloC1-C4alkyl, cyano, C1-C4alkyl, Ar1, HET1, C1-C4alkoxy, —O—Ar1, —O-HET1, haloC1-C4alkoxy, hydroxy, amino, or aminoC1-C4alkyl;
Ar1 is phenyl, biphenyl, or naphthyl;
HET1 is pyrrole, furyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, triazinyl, quinolinyl, isoquinolinyl, indolyl, benzofuranyl, benzothienyl, isoindolyl, indazolyl, benzoisoxazolyl, benzoisothiazolyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, or benzotriazolyl;
d is an integer of 0 to 5, and when d is an integer of 2 or more, R4 may be the same as or different from each other.

### Claim 11 (depends on 10)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 10, wherein
R3 is C1-C4 alkyl or C1-C4 alkoxy, or is selected from the following structures:
wherein R21 to R26 are independently of one another C1-C4alkyl, halogen, haloC1-C4alkyl, nitro, C1-C4alkylcarbonylamino, amino, C1-C4alkoxy, haloC1-C4alkoxy, C1-C4alkoxyC1-C4alkoxy, hydroxy, haloC1-C4alkylcarbonyl, carboxyl, diC1-C4alkylaminoC1-C4alkoxy, dihydroxyaminosulfanyl, C1-C4alkylsulfonyl, C6-C12aryl, or C2-C12heteroaryl;
Z is —(CR27R28)x—;
R27 and R28 are independently of each other hydrogen, C1-C4alkyl, or halogen;
x is an integer of 1 to 3;
R″ is hydrogen or C1-C4alkyl; and
r is an integer of 0 to 3, and when r is an integer of 2 or more, R21 may be the same as or different from each other; s is an integer of 0 to 2, and when s is an integer of 2 or more, R22 may be the same as or different from each other; t is an integer of 0 to 4, and when t is an integer of 2 or more, R23 may be the same as or different from each other; u is an integer of 0 to 5, and when u is an integer of 2 or more, R24 may be the same as or different from each other; v is an integer of 0 to 6, and when v is an integer of 2 or more, R25 may be the same as or different from each other; and w is an integer of 0 to 7, and when w is an integer of 2 or more, R26 may be the same as or different from each other.

### Claim 12 (depends on 1)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 1, wherein the compound is any one selected from the following:

### Claim 13 (depends on 1)

A pharmaceutical composition for preventing or treating cancer comprising the compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 1 as an effective component.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the cancer is lung cancer, colorectal cancer, colon cancer, rectal cancer, breast cancer, prostate cancer, bladder cancer, blood cancer, leukemia, myelogenous leukemia, lymphoma, cervical carcinoma, osteosarcoma, glioblastoma, melanoma, pancreatic cancer, gastric cancer, liver cancer, kidney cancer, gallbladder cancer, biliary tract cancer, esophageal cancer, ovarian cancer, thyroid cancer, skin cancer, or neuroblastoma.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13, further comprising a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 16 (depends on 1)

A YAP/TAZ-TEAD inhibitor composition comprising the compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 1 as an effective component.

### Claim 17 (depends on 1)

A health functional food composition for preventing or improving cancer comprising the compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 1 as an effective component.

### Claim 18 (depends on 5)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 5, wherein
R1 is hydrogen or —(CH2)n—R;
R is C1-C6alkoxy, C6-C12aryloxy, hydroxy, cyano, halogen, nitro, C1-C6alkylsulfanyl, C6-C12arylsulfanyl, sulfanyl, —NRa1Ra2, C1-C6alkoxyC1-C6alkyl, C6-C12aryloxyC1-C6alkyl, C1-C6alkoxyC1-C6alkoxy, C1-C6alkoxyC1-C6alkoxyC1-C6alkyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C1-C6alkylC6-C12arylsulfonyl, C6-C12arylC1-C6alkylsulfonyl, sulfo, C6-C12aryl, C1-C6alkoxycarbonyl, C6-C12aryloxycarbonyl, carboxyl, formyl, C2-C12heteroaryl, or C3-C12heterocycloalkyl, and the aryl, heteroaryl, and heterocycloalkyl of R may be further substituted by one or more substituents selected from the group consisting of C1-C6alkyl, halogen, nitro, cyano, hydroxy, C1-C6alkoxy, C6-C12aryloxy, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C1-C6alkylC6-C12arylsulfonyl, C6-C12arylC1-C6alkylsulfonyl, carboxyl, sulfo, formyl, carbamoyl, sulfamoyl, and amino;
Ra1 and Ra2 are independently of each other hydrogen, C1-C6alkyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C1-C6alkylC6-C12arylsulfonyl, C6-C12arylC1-C6alkylsulfonyl, sulfo, or sulfamoyl;
n is an integer of 1 to 5;
R2 is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl, or C6-C12aryloxyC1-C6alkyl;
R3 is C1-C6alkyl, C1-C6alkoxy, C6-C12aryloxy, C3-C12heterocycloalkyl, C6-C12aryl, or C2-C12heteroaryl;
R3a is C3-C12heterocycloalkyl, C6-C12aryl, or C2-C12heteroaryl;
the heterocycloalkyl, aryl, and heteroaryl of R3 and R3a may be further substituted by one or more substituents selected from the group consisting of C1-C6alkyl, halogen, haloC1-C6alkyl, nitro, cyano, C1-C6alkylcarbonylamino, C6-C12arylcarbonylamino, amino, C1-C6alkoxy, haloC1-C6alkoxy, C1-C6alkoxyC1-C6alkoxy, C6-C12aryloxy, hydroxy, C1-C6alkylcarbonyl, haloC1-C6alkylcarbonyl, C6-C12arylcarbonyl, carboxyl, formyl, sulfanyl, C1-C6alkylsulfanyl, C6-C12arylsulfanyl, diC1-C6alkylaminoC1-C6alkoxy, dihydroxyaminosulfanyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, sulfo, carbamoyl, C1-C6alkylaminocarbonyl, C6-C12arylaminocarbonyl, sulfamoyl, C1-C6alkylaminosulfonyl, C6-C12arylaminosulfonyl, C6-C12aryl, C2-C12heteroaryl, and C3-C12heterocycloalkyl;
La is C1-C5alkylene;
R4 is halogen, haloC1-C6alkyl, cyano, C1-C6alkyl, C6-C12aryl, C2-C12heteroaryl, C1-C6alkoxy, C6-C12aryloxy, C2-C12heteroaryloxy, haloC1-C6alkoxy, hydroxy, amino, or aminoC1-C6alkyl; and
d is an integer of 0 to 5, and when d is an integer of 2 or more, R4 may be the same as or different from each other.

### Claim 19 (depends on 18)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 18, wherein
R1 is hydrogen or —(CH2)n—R;
R is C1-C6alkoxy, hydroxy, cyano, halogen, C1-C6alkylsulfanyl, —NRa1Ra2, C1-C6alkoxyC1-C6alkyl, C1-C6alkoxyC1-C6alkoxy, C1-C6alkoxyC1-C6alkoxyC1-C6alkyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C6-C12aryl, C1-C6alkoxycarbonyl, C6-C12aryloxycarbonyl, C2-C12heteroaryl, or C3-C12heterocycloalkyl, and the aryl, heteroaryl, and heterocycloalkyl of R may be further substituted by one or more substituents selected from the group consisting of C1-C6alkyl, halogen, nitro, cyano, hydroxy, C1-C6alkoxy, C6-C12aryloxy, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, C1-C6alkylC6-C12arylsulfonyl, C6-C12arylC1-C6alkylsulfonyl, carboxyl, sulfo, and formyl;
Ra1 and Ra2 is independently of each other C1-C6alkyl, C1-C6alkylsulfonyl, or C6-C12arylsulfonyl;
n is an integer of 1 to 3;
R2 is hydrogen or C1-C6alkoxyC1-C6alkyl;
R3 is C1-C6alkyl, C1-C6alkoxy, C3-C12heterocycloalkyl, C6-C12aryl, or C2-C12heteroaryl;
R3a is C3-C12heterocycloalkyl, C6-C12aryl, or C2-C12heteroaryl;
the heterocycloalkyl, aryl, and heteroaryl of R3 and R3a may be further substituted by one or more substituents selected from the group consisting of C1-C6alkyl, halogen, haloC1-C6alkyl, nitro, cyano, C1-C6alkylcarbonylamino, C6-C12arylcarbonylamino, amino, C1-C6alkoxy, haloC1-C6alkoxy, C1-C6alkoxyC1-C6alkoxy, hydroxy, C1-C6alkylcarbonyl, haloC1-C6alkylcarbonyl, C6-C12arylcarbonyl, carboxyl, formyl, sulfanyl, C1-C6alkylsulfanyl, C6-C12arylsulfanyl, diC1-C6alkylaminoC1-C6alkoxy, dihydroxyaminosulfanyl, C1-C6alkylsulfonyl, C6-C12arylsulfonyl, sulfo, carbamoyl, sulfamoyl, C6-C12aryl, C2-C12heteroaryl, and C3-C12heterocycloalkyl;
R4 is halogen, haloC1-C6alkyl, cyano, C1-C6alkyl, C6-C12aryl, C2-C12heteroaryl, C1-C6alkoxy, C6-C12aryloxy, C2-C12heteroaryloxy, haloC1-C6alkoxy, hydroxy, amino, or aminoC1-C6alkyl; and
d is an integer of 0 to 5, and when d is an integer of 2 or more, R4 may be the same as or different from each other.

### Claim 20 (depends on 19)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 19, wherein R1 is hydrogen.

### Claim 21 (depends on 19)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 19, wherein
R1 is —(CH2)n—OR11, —(CH2)n—OH, —(CH2)n—CN, —(CH2)n—X1, —(CH2)n—SR12, —(CH2)n—NR13R14, —(CH2)n—NR13—SO2R15, —(CH2)n-L1-OR11, —(CH2)n—SO2R1-6, or —(CH2)n—C(═O)OR17, or is selected from the following structures:
wherein R11 is C1-C4alkyl or C1-C4alkoxyC1-C4alkyl;
X1 is halogen;
R12 to R14 are independently of each other C1-C4alkyl;
R15, R16, R17, and R20 are independently of one another C1-C4alkyl or C6-C12aryl;
L1 is C1-C4 alkylene;
R18 and R19 are independently of each other C1-C4alkyl, halogen, nitro, cyano, hydroxy, C1-C4alkoxy, C6-C12aryloxy, carboxyl, sulfo, or formyl;
R′ is hydrogen or C1-C4alkyl;
Q is CH2, NH, O, or S;
n is an integer of 1 to 3;
p is an integer of 0 to 5, and when p is an integer of 2 or more, R18 may be the same as or different from each other; and
q is an integer of 0 to 4, and when q is an integer of 2 or more, R19 may be the same or different from each other.

### Claim 22 (depends on 19)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 19, wherein
R2 is hydrogen or C1-C4alkoxyC1-C4alkyl;
R3 is selected from C1-C4alkyl, C1-C4alkoxy, or the following structures:
R21 to R26 are independently of each one another C1-C4alkyl, halogen, haloC1-C4alkyl, nitro, cyano, C1-C4alkylcarbonylamino, C6-C12arylcarbonylamino, amino, C1-C4alkoxy, haloC1-C4alkoxy, C1-C4alkoxyC1-C4alkoxy, hydroxy, C1-C4alkylcarbonyl, haloC1-C4alkylcarbonyl, C6-C12arylcarbonyl, carboxyl, formyl, sulfanyl, C1-C4alkylsulfanyl, C6-C12arylsulfanyl, diC1-C4alkylaminoC1-C4alkoxy, dihydroxyaminosulfanyl, C1-C4alkylsulfonyl, C6-C12arylsulfonyl, sulfo, carbamoyl, sulfamoyl, C6-C12aryl, C2-C12heteroaryl, or C3-C12heterocycloalkyl;
Y1 and Y2 are independently of each other NR″, O, or S;
Z is —(CR27R28)x—;
R27 and R28 are independently of each other hydrogen, C1-C4alkyl, or halogen;
x is an integer of 1 to 3;
T is CH2 or O;
R″ is hydrogen or C1-C4alkyl; and
r is an integer of 0 to 3, and when r is an integer of 2 or more, R21 may be the same as or different from each other; s is an integer of 0 to 2, and when s is an integer of 2 or more, R22 may be the same as or different from each other; t is an integer of 0 to 4, and when t is an integer of 2 or more, R23 may be the same as or different from each other; u is an integer of 0 to 5, and when u is an integer of 2 or more, R24 may be the same as or different from each other; v is an integer of 0 to 6, and when v is an integer of 2 or more, R25 may be the same as or different from each other; and w is an integer of 0 to 7, and when w is an integer of 2 or more, R26 may be the same as or different from each other;
R4 is halogen, haloC1-C4alkyl, cyano, C1-C4alkyl, Ar1, HET1, C1-C4alkoxy, —O—Ar1, —O-HET1, haloC1-C4alkoxy, hydroxy, amino, or aminoC1-C4alkyl;
Ar1 is phenyl, biphenyl, or naphthyl;
HET1 is pyrrole, furyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, triazinyl, quinolinyl, isoquinolinyl, indolyl, benzofuranyl, benzothienyl, isoindolyl, indazolyl, benzoisoxazolyl, benzoisothiazolyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, or benzotriazolyl;
d is an integer of 0 to 5, and when d is an integer of 2 or more, R4 may be the same as or different from each other.

### Claim 23 (depends on 22)

The compound, the prodrug thereof, the hydrate thereof, the solvate thereof, or the pharmaceutically acceptable salt thereof of claim 22, wherein
R3 is C1-C4 alkyl or C1-C4 alkoxy, or is selected from the following structures:
wherein R21 to R26 are independently of one another C1-C4alkyl, halogen, haloC1-C4alkyl, nitro, C1-C4alkylcarbonylamino, amino, C1-C4alkoxy, haloC1-C4alkoxy, C1-C4alkoxyC1-C4alkoxy, hydroxy, haloC1-C4alkylcarbonyl, carboxyl, diC1-C4alkylaminoC1-C4alkoxy, dihydroxyaminosulfanyl, C1-C4alkylsulfonyl, C6-C12aryl, or C2-C12heteroaryl;
Z is —(CR27R28)x—;
R27 and R28 are independently of each other hydrogen, C1-C4alkyl, or halogen;
x is an integer of 1 to 3;
R″ is hydrogen or C1-C4alkyl; and
r is an integer of 0 to 3, and when r is an integer of 2 or more, R21 may be the same as or different from each other; s is an integer of 0 to 2, and when s is an integer of 2 or more, R22 may be the same as or different from each other; t is an integer of 0 to 4, and when t is an integer of 2 or more, R23 may be the same as or different from each other; u is an integer of 0 to 5, and when u is an integer of 2 or more, R24 may be the same as or different from each other; v is an integer of 0 to 6, and when v is an integer of 2 or more, R25 may be the same as or different from each other; and w is an integer of 0 to 7, and when w is an integer of 2 or more, R26 may be the same as or different from each other.
